Alexion to Acquire Wilson Therapeutics: Click Here For Transaction Details and Disclosures
Share, Send, or Save

Soliris® (eculizumab) and Generalized Myasthenia Gravis

Soliris® ;is the first and only complement inhibitor for patients with generalized myasthenia gravis (gMG), a chronic and debilitating neuromuscular disorder.1


Myasthenia gravis (MG) is a debilitating, chronic and progressive autoimmune neuromuscular disease that can occur at any age but most commonly begins for women before the age of 40 and men after the age of 60.2-5 It typically begins with weakness in the muscles that control the movements of the eyes and eyelids, and often progresses to the more severe and generalized form, known as gMG, with weakness of the head, neck, trunk, limb and respiratory muscles.5

Patients with gMG can suffer from slurred speech; choking; impaired swallowing; double or blurred vision; disabling fatigue; immobility requiring assistance; shortness of breath; and episodes of respiratory failure. Complications, exacerbations and myasthenic crises can require hospital and intensive care unit admissions with prolonged stays and can be life-threatening.3,4,6 While most gMG symptoms can be managed with existing MG therapies, 10-15% of patients fail to respond adequately to or cannot tolerate multiple therapies for MG and continue to suffer profound muscle weakness and severe disease symptoms that limit function.7-9

In patients with anti-acetycholine receptor (AchR) antibody-positive MG, the body’s own immune system turns on itself to produce antibodies against AchR, a receptor that plays an important role in the communication between nerves and muscles.3,4 The binding of these antibodies to AchR activates the complement cascade, another part of the immune system, which leads to localized destruction of the neuromuscular junction.10-12


Soliris®  is the first and only complement inhibitor approved for the treatment of adult patients with gMG who are anti-AchR antibody-positive. The safety and efficacy of Soliris®  for the treatment of gMG were established in a 26-week Phase 3, randomized, double-blind, placebo-controlled, multicenter clinical study (REGAIN, ECU-MG-301, N=125).

The primary efficacy endpoint was a comparison of the change from baseline between Soliris®  and placebo in MG-Activities of Daily Living (MG-ADL) total score at week 26. See detailed results of the REGAIN Study and Interim Analysis from Phase 3 Open-Label Extension Study.

The most frequently reported adverse reaction in the gMG placebo-controlled trial (≥10%) is: musculoskeletal pain.

Quick Links



Life-threatening and fatal meningococcal infections have occurred in patients treated with Soliris® . Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early.

  • Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies.
  • Immunize patients with meningococcal vaccines at least 2 weeks prior to administering the first dose of Soliris® , unless the risks of delaying Soliris®  therapy outweigh the risk of developing a meningococcal infection.
  • Monitor patients for early signs of meningococcal infections and evaluate immediately if infection is suspected.

Soliris®  is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the Soliris®  REMS, prescribers must enroll in the program. Enrollment in the Soliris®  REMS program and additional information are available by telephone: 1-888-SOLIRIS® (1-888-765-4747) or at

Indications and Usage

Paroxysmal Nocturnal Hemoglobinuria (PNH)
Soliris®  is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.

Atypical Hemolytic Uremic Syndrome (aHUS)
Soliris®  is indicated for the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy.

Limitation of Use
Soliris®  is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).

Generalized Myasthenia Gravis (gMG)
Soliris®  is indicated for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive.


Soliris®  is contraindicated in:

  • Patients with unresolved serious Neisseria meningitidis infection
  • Patients who are not currently vaccinated against Neisseria meningitidis, unless the risks of delaying Soliris®  treatment outweigh the risks of developing a meningococcal infection

Warnings and Precautions

Other Infections
Soliris®  blocks terminal complement activation; therefore patients may have increased susceptibility to infections, especially with encapsulated bacteria. Additionally, Aspergillus infections have occurred in immunocompromised and neutropenic patients. Children treated with Soliris®  may be at increased risk of developing serious infections due to Streptococcus pneumoniae and Haemophilus influenza type b (Hib). Administer vaccinations for the prevention of Streptococcus pneumoniae and Haemophilus influenza type b (Hib) infections according to ACIP guidelines. Use caution when administering Soliris®  to patients with any systemic infection.

Monitoring Disease Manifestations After Soliris®  Discontinuation
Treatment Discontinuation for PNH
Monitor patients after discontinuing Soliris®  for at least 8 weeks to detect hemolysis.

Treatment Discontinuation for aHUS
After discontinuing Soliris® , monitor patients with aHUS for signs and symptoms of thrombotic microangiopathy (TMA) complications for at least 12 weeks. In aHUS clinical trials, 18 patients (5 in the prospective studies) discontinued Soliris®  treatment. TMA complications occurred following a missed dose in 5 patients, and Soliris®  was reinitiated in 4 of these 5 patients.

Clinical signs and symptoms of TMA include changes in mental status, seizures, angina, dyspnea, or thrombosis. In addition, the following changes in laboratory parameters may identify a TMA complication: occurrence of two, or repeated measurement of any one of the following: a decrease in platelet count by 25% or more compared to baseline or the peak platelet count during Soliris®  treatment; an increase in serum creatinine by 25% or more compared to baseline or nadir during Soliris®  treatment; or, an increase in serum LDH by 25% or more over baseline or nadir during Soliris®  treatment.

If TMA complications occur after Soliris®  discontinuation, consider reinstitution of Soliris®  treatment, plasma therapy [plasmapheresis, plasma exchange, or fresh frozen plasma infusion (PE/PI)], or appropriate organ-specific supportive measures.

Thrombosis Prevention and Management
The effect of withdrawal of anticoagulant therapy during Soliris®  treatment has not been established. Therefore, treatment with Soliris®  should not alter anticoagulant management.

Infusion Reactions
Administration of Soliris®  may result in infusion reactions, including anaphylaxis or other hypersensitivity reactions. In clinical trials, no patients experienced an infusion reaction which required discontinuation of Soliris® . Interrupt Soliris®  infusion and institute appropriate supportive measures if signs of cardiovascular instability or respiratory compromise occur.

Adverse Reactions

The most frequently reported adverse reactions in the PNH randomized trial (≥10% overall and greater than placebo) are: headache, nasopharyngitis, back pain, and nausea.

The most frequently reported adverse reactions in aHUS single arm prospective trials (≥20%) are: headache, diarrhea, hypertension, upper respiratory infection, abdominal pain, vomiting, nasopharyngitis, anemia, cough, peripheral edema, nausea, urinary tract infections, pyrexia.

The most frequently reported adverse reaction in the gMG placebo-controlled clinical trial (≥10%) is: musculoskeletal pain.

Please see full prescribing information for Soliris® , including boxed WARNING regarding serious meningococcal infection.


  1. Soliris®  [package insert]. New Haven, CT: Alexion Pharmaceuticals Inc; 2017
  2. Huda R, Tüzün E, Christadoss P. Targeting complement system to treat myasthenia gravis. Rev. Neurosci. 2014; 25(4): 575–583.
  3. Howard JF, Barohn RJ, Cutter GR et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. 2013;48(1):76-84.
  4. National Institute of Neurological Disorders and Stroke. Myasthenia Gravis Fact Sheet. Publication date May 2017.
  5. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475-490.
  6. Sathasivam S. Diagnosis and management of myasthenia gravis. Progress in Neurology and Psychiatry. January/February 2014.
  7. Silvestri N, Wolfe G. Treatment-refractory myasthenia gravis. J. Clin Neuromuscul Dis. 2014;15(4):167-178.
  8. Howard J. Targeting the Complement System in Refractory Myasthenia Gravis. Supplement to Neurology Reviews. February 2016.
  9. Sanders DB, Wolfe, GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016;87(4):419-25.
  10. Conti-Fine, et al. Myasthenia gravis: past, present, and future. J Clin Invest. 2006; 116:2843-2354.
  11. Tüzün E, Huda R, Christadoss P. Complement and cytokine based therapeutic strategies in myasthenia gravis. J Autoimmun. 2011;37(2):136-143.
  12. Meriggioli MN, Sanders DB. Muscle autoantibodies in myasthenia gravis: beyond diagnosis? Expert Rev. Clin. Immunol. 2012;8(5), 427-428.